After struggling with its sole drug for years, Marinus rides positive data to a commercialization deal in Europe
After a series of painful setbacks, Marinus had a rebirth of sorts last year when it offered a positive late-stage preview of its sole drug, ganaxolone, in a genetic disorder that causes early-onset epilepsy. Now, CEO Scott Braunstein is riding that success to an NDA submission and a collaboration with the Finnish pharma company Orion to commercialize the candidate in Europe.
Orion is putting down around $30 million upfront (€25 million) and $115 million in biobucks (€97 million) for exclusive rights to market both the oral and IV formulations of ganaxolone in the EU, UK and Switzerland for the treatment of CDKL5 deficiency disorder (CDD), tuberous sclerosis complex (TSC) and refractory status epilepticus (RSE).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.